The role of B7-2 (CD86) in tumour immunity

Bibliography

• SCHWARTZ RH: Co-stimulation of T lymphocytes: the role of CD28, CTLA4, and B7/BB1 in interleukin-2 pro-duction and immunotherapy. Cell (1992) 71:1065–1068.
   PubMed Web of Science ®Google Scholar
• MUELLER DL, JENKINS MK, SCHWARTZ RH: Clonal expan-sion versus functional clonal inactivation: a co-stimu-latory signalling pathway determines the outcome of T-cell antigen receptor occupancy. Ann. Rev. Immunol (1989) 7:445–480.
   PubMed Web of Science ®Google Scholar
• JUNE CH, BLUESTONE JA, NADLER LM, THOMPSON CB:
   Google Scholar
• •The B7 and CD28 receptor families. Immunol. Today (1994) 15:321-331. An excellent review proposing a temporal model of B7/CD28 co-stimulation.
   Google Scholar
• LENSCHOW DJ, WALUNAS TL, BLUESTONE JA: CD28/B7 system of T-cell co-stimulation. Ann. Rev. Immunol (1996) 14:233–258.
   PubMed Web of Science ®Google Scholar
• CHEN L, LINSLEY PS, HELLSTROM KE: Costimulation of T-cells for tumor immunity. Immunol. Today (1993) 14:483–496.
   PubMedGoogle Scholar
• HELLSTROM KE, HELLSTROM I, CHEN L: Can co-stimu-
   Google Scholar
• ?lated tumor immunity be therapeutically efficacious? Immunol Rev. (1995) 145:123-145. An extensive review of B7-1 co-stimulation in tumour immunity.
   Google Scholar
• ALLISON JP, HURWITZ AA, LEACH DR: Manipulation of costimulatory signals to enhance antitumor T-cell re-sponses. Curr. Opin. Immunol (1995) 7:682–686.
   PubMed Web of Science ®Google Scholar
• NICKLOFF BJ, MITRA RS, LEE K eta].: Discordant expres-sion of CD28 ligands, BB-1 and B7 on keratinocytes in vitro and psoriatic cells in vivo. Am. J. Pathol. (1993) 142:1029–1040.
   Google Scholar
• HATHCOCK KS, LASZLO G, DICKLER HB et al.: Identifica-tion of an alternative CTLA-4 ligand costimulatory for T-cell activation. Science (1993) 262:905–907.
   PubMed Web of Science ®Google Scholar
• WU Y, GUO Y, LIU Y: A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7. J. Exp. Mod. (1993) 178:1789–1793.
   PubMed Web of Science ®Google Scholar
• FREEMAN GJ, BORRIELLO F, HODES RJ etal: Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science (1993) 262:907-909. First report demonstrating B7-2 co-stimulation in B7-1 knockout mice.
   Google Scholar
• FREEMAN GJ, GRIBBEN JG, BOUSSIOTIS VA et aL: Cloning of B 7–2: a CTLA-4 counter-receptor that costimulateshuman T-cell proliferation. Science (1993) 262:909-911. See annotation [14].
   Google Scholar
• FREEMAN GJ, BORRIELLO F, HODES RJ eta].: Murine B7–2, an alternative CTLA4 counter-receptor that costimu-lates T-cell proliferation and interleukin 2 production. J. Exp. Med. (1993) 178:2185-2192. See annotation [14].
   Google Scholar
• AZUMA M, ITO D, YAGITA H eta].: B70 antigen is a second ligand for CTLA-4 and CD28. Nature (1993) 366:76-79.This paper and [12,13] contain first reports of the B7-2 gene and its function.
   Google Scholar
• CAUX C, VANBERVLIET B, MASSACRIER C eta].:B70/137-2is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J. Exp. Med. (1994) 180:1841–1847.
   Google Scholar
• LINSLEY PS, GREENE J, BRADY W et al.: Human B7–1
   Google Scholar
• •(CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immu-nity (1994) 1:793-801. A detail study of binding characteristics between B7 family members.
   Google Scholar
• INABA K, WITMER-PACK M, ANABA M et al: The tissue distribution of the B7–2 costimulator in mice: abundant expression on dendritic cells in situ and during matu- ration in vitro. J Exp. Med (1994) 180:1849-1860. An extensive study of tissue distribution of B7-2 and kinetics of its expression
   Google Scholar
• HANCOCK WW, SAYEGH MH, ZHENG X-G eta].: Costimu-latory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft re-jection. Proc. Natl. Acad. Sci USA (1996) 93:13967–13972.
   Google Scholar
• KRUMMAL MF, ALLISON JP: CD28 and CTLA-4 have op-posing effects on the response of T-cells to stimulation. J. Exp. Med (1995) 182:459–465.
   PubMed Web of Science ®Google Scholar
• HATHCOCK KS, LASZLO G, PUCILLO C, LINSLEY P, HODESRJ: Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. (1994) 180:631–640.
   PubMed Web of Science ®Google Scholar
• CAUXC, MASSACRIER C, VANBERVLIET B eta].: Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med (1994) 180:1263–1272.
   Google Scholar
• LANIER LL, O'FALLON S, SOMOZA C eta].: CD80 On and CD86 (370) provide similar costimulatory signals for T-cell proliferation, cytokine production, and genera-tion of CTL. J. Immunol (1995) 154:97–105.
   Google Scholar
• LEVINE BL, UEDA Y, CRAIGHEAD N, HUANG ML, JUNE CH: CD28 ligands CD80 (B7-1) and CD86 07-4 induce long-term autocrine growth of CD4+ T-cells and induce similar patterns of cytokine secretion in vitro. Int Immunol (1995) 7:891–904.
   PubMed Web of Science ®Google Scholar
• YANG G, HELLSTROM KE, MIZUNO MT, CHEN L: In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J. Immu-nol. (1995) 155:3897–3903.
   PubMed Web of Science ®Google Scholar
• GADJEWSKI TF: B7-1 but not B7-2 efficiently costimu-lates CD8+ T lymphocytes in the P815 tumor system in vitro. J. Immunol (1996) 156:116–472.
   Google Scholar
• YI-QUN Z, VAN NEERVEN RJ, KASRAN A, DE BOER M, CEUPPENS JL: Differential requirements for co-stimula-tory signals from B7 family members by resting versus recently activated memory T-cells towards soluble re-call antigens. Int. Immunol (1995) 8:37–44.
   Web of Science ®Google Scholar
• CHEN C, NABAVI N: In vitro induction of T-cell energy by blocking B7 and early T-cell costimulatory molecule ETC-1B7-2. Immunity (1994) 1:147–154.
   PubMed Web of Science ®Google Scholar
• BASHUDA H, SEINO K, KANO M eta].: Specific acceptance of cardiac allografts after treatment with antibodies to CD80 and CD86 in mice. Transplant. Proc. (1996) 28:1039–1041.
   Google Scholar
• BLAZAR BR, SHARPE AH, TAYLOR PA eta].: Infusion ofanti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal an-tibodies inhibits murine graft versus host disease le-thality in part via direct effects on CD4+ and CD8+ T-cells. j Immunol (1996). 157: 3250–3259.
   Google Scholar
• SAITO K, YAGITA H, HASHIMOTO H, OKUMURA K, AZUMA M: Effect of CD80 and CD86 blockade and anti-interleukin-12 treatment on mouse acute graft ver-sus host disease. Eur. j Immunol (1996) 26:3098–3106.
   PubMed Web of Science ®Google Scholar
• HATHCOCK KS, HODES RJ: Role of the CD28-B7 costimu-latory pathways in T-cell-dependent B-cell responses. Adv. Immunol (1996) 62:131–166.
   PubMed Web of Science ®Google Scholar
• SCHVVEITZER AN, BORRIELLO F, WONG RCK, ABBAS AK,SHARPE AH: Role of costimulators in T-cell differentia-tion: studies using antigen-presenting cells lacking ex-pression of CD80 or CD86. J. Immunol (1997) 158:2713–2722.
   PubMedGoogle Scholar
• FREEMAN GJ, BOUSSIOTIS VA, ANUMANTHAN A et al.:B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimu-lates the initial production of 11-4. Immunity (1995) 2:523–532.
   PubMed Web of Science ®Google Scholar
• KUCHROO VK, DAS MP, BROWN JA et al: B7-1 and B7-2 costimulatory molecules activate differentially the Thl/Th2 developmental pathways: application to autoimmune disease therapy. Cell (1995) 80:707–718.
   PubMed Web of Science ®Google Scholar
• RACKE MK, SCOTT DE, QUIGLEY L et al: Distinct role for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest (1995) 96:2195–2203.
   PubMed Web of Science ®Google Scholar
• SEDER RA, GERMAIN RN, LINSLEY PS, PAUL WE: CD28-me-diated costimulation of interleukin 2 (11-2) production plays a critical role in T-cell priming for IL-4 and interferon y production. J. Exp. Med (1994) 179:299–304.
   PubMed Web of Science ®Google Scholar
• NATESAN M, RAZI-WOLF Z, REISER H: Costimulation of IL-4 production by murine B7-1 and B7-2 molecules. J. Immunol (1996) 156:2783–2791.
   PubMed Web of Science ®Google Scholar
• LENSCHOW DJ, HO SC, SATTAR H et aL: Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the non-obese diabetic mouse. J. Exp. Med. (1995) 181:1145–1155.
   PubMed Web of Science ®Google Scholar
• SAYEGH MH, AKALIN E, HANCOCK WW et al: CD28-B7blockade after alloantigenic challenge in vivo inhibits Thl cytokines but spares Th2. J. Exp. Med. (1995) 181:1869–1874.
   PubMed Web of Science ®Google Scholar
• CORRY DB, REINER SL, LINSLEYPS, LOCKSLEY RM: Differ-ential effects of blockade of CD28-B7 on the develop-ment of Thl or Th2 effector cells in experimental le ishmaniasis Immunol. (1994) 153:4142-4148.
   Google Scholar
• RULIFSON IC, SPERLING Al, FIELDS PE, FITCH FW,BLUESTONE JA: CD28 costimulation promotes the pro-duction of Th2 cytokines. j Immunol (1997) 158:658–665.
   PubMed Web of Science ®Google Scholar
• WU Y, GUO Y, HUANG A, ZHENG P, LIU Y: CTLA-4-B7 interaction is sufficient to costimulate T-cell clonal expansion. J. Exp. Med (1997) 185:1–9.
   PubMedGoogle Scholar
• WALUNAS TL, LENSCHOW DJ, BAKKER CY et al.: CTLA-4 can function as a negative regulator of T-cell activation. Immunity (1994) 1:405–413.
   PubMed Web of Science ®Google Scholar
• KRUMMEL MF, ALLISON JP: CD28 and CTLA-4 have op-posing effects on the response of T-cells to stimulation. J. Exp. Med (1995) 182:459–465.
   PubMed Web of Science ®Google Scholar
• YANG G, MIZUNO MT, HELLSTROM KE, CHEN L: B7-negative versus B7-positive P815 tumor: differential re quire - me nts for priming of an antitumor immune response in lymph nodes. J. Immunol (1997) 158:851-858. This paper shows the requirement for host-derived B7 in rejection of B7-negative tumour.
   Google Scholar
• CHAUX P, MARTIN MS, MARTIN F: T-cell co-stimulationby the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneous regres-sive tumor. Int. J. Cancer. (1996) 66:244–248.
   PubMed Web of Science ®Google Scholar
• CHEN L, MCGOWAN P, ASHE S et al.: Tumor immuno-genicity determines the effect of B7 costimulation on T-cell-mediated tumor immunity. J. Exp. Med. (1994) 179:523–532.
   PubMed Web of Science ®Google Scholar
• ZITVO GEL L, MAYORDOMO JI, TJANDRAWAN T et aL:
   Google Scholar
• •Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T-cells, B7 costimula-tion, and T-helper cell 1-associated cytokines. J. Exp. Med. (1996) 183:87-97. A detailed study on the mechanism of dendritic cell-mediated antitumour immunity.
   Google Scholar
• YANG G, HELLSTROM KE, HELLSTROM I, CHEN L: Antitu-
   Google Scholar
• ?mor immunity elicited by tumor cells transfected with B7–2, a second ligand for (D28/CTLA4 costimulatory molecules. J. Immunol (1995) 154:2794-2800. This paper demonstrates that B7-2+ tumour cells induce tumour rejection and protective immunity, which is mediated by CD8+ CTL.
   Google Scholar
• GAJEWSKI TF, FALLARINO F, UYTTENHOVE C, BOON T:
   Google Scholar
• ••Tumor rejection requires a CTLA4 ligand provided bythe host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol (1996) 156:2909-2917. This paper shows that immunisation with B7-1+ tumour cells is superior to that with B7-2+ tumour cells for protective immunity.
   Google Scholar
• LA MOTTE RN, RUBIN MA, BARR E et al: Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol. Immunother. (1996) 42:161–169.
   PubMed Web of Science ®Google Scholar
• MATULONIS U, DOSIOU C, FREEMAN G et al.: B7-1 is superior to B7-2 costimulation in the induction and maintenance of T-cell-mediated antileukemia immu-nity: further evidence that B7-1 and B7-2 are function-ally distinct. J. Immunol (1996) 156:1126–1131.
   PubMed Web of Science ®Google Scholar
• MARTIN-FONTECHA A, CAVALLO F, BELLONE M et al.:
   Google Scholar
• ••Heterogeneous effects of B7–1 and B 7–2 in the inductionof both protective and therapeutic antitumor immunity against different mouse tumors. Eur. j Immunol. (1996) 26:1851-1859. A careful comparison study of B7-1+ and B7-2+ tumour cells in the induction of antitumour immunity.
   Google Scholar
• HODGE JW, ABRAMS S, SCHLOM J, KANTON JA: Induction of antitumor immunity by recombinant vaccinia virus expressing B7-1 or B7-2 costimulatory molecules. Can-cer Res. (1994) 54:5552–5555.
   PubMed Web of Science ®Google Scholar
• BASKAR S, CLEMENTS VK, GLIMCHER LH, NABAVI N, OSTRAND-ROSENBERG S: Rejection of MHC class II-transfected tumor cells requires induction of tumor encoded B7-1 and/or B7-2 costimulatory molecules. J. Immunol (1996) 156:3821–3827.
   PubMed Web of Science ®Google Scholar
• CHONG H, HUTCHINSON G, HART IR, VILE RG: Expres-sion of co-stimulatory molecules by tumor cells de-creases turnorigenecity but may also reduce syslemic antitumor immunity. Hum. Gene Ther. (1996) 7:1771–1779.
   PubMed Web of Science ®Google Scholar
• RESTIFO NP, ESQUIVEL F, KAWAKAMI Yet al.: Identifica-tion of human cancers deficient in antigen processing. J. Exp. Med (1993) 177:265–272.
   Google Scholar
• LI Y, HELLSTROM KE, NEWBY SA, CHEN L: Costimulation by CD48 and B7-1 induces immunity against poorly-im- munogenic tumors. J. Exp. Med (1996) 183:639–644.
   PubMed Web of Science ®Google Scholar
• CAVALLO F, MARTIN-FONTECHA A, BELLONE M et aL: Co-expression of B7-1 and HAM-1 on tumors is re-quired for rejection and establishment of a memory response. Eur. j Immund (1995) 25:1154–1162.
   PubMed Web of Science ®Google Scholar
• BIERER BE, HAHN WC: T-cell adhesion, avidity regula-tion and signaling: a molecular analysis of CD 2. Semin. Immunol (1993) 5:249–261.
   PubMedGoogle Scholar
• PARDI R, BENDER JR, DETTORI C, GIANNZZA, ENGLEMAN EG: Heterogeneous distribution and transmembrane signaling properties of lymphocyte function-associated antigen (LFA-1) in human lymphocyte subsets. J. Immu-nol. (1989) 143:3157–3166.
   PubMed Web of Science ®Google Scholar
• MCHUGH RS, AHMED SN, WANG Y-C, SELL KW, SELVARAJP: Construction, purification, and functional incorpo-ration on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc. Natl. Acad. Sci. USA (1995) 92:8059–8063.
   PubMed Web of Science ®Google Scholar
• BRUNSCHWIG EB, LEVINE E, TREFZER U, TYKOCINSKI ML:Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulat or function. J. Immunol (1995) 155:5498–5505.
   PubMedGoogle Scholar
• CHIOINI HA, WENDTNER CM, URCELAY E et aL: High-ef-ficiency transfer of the T-cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. Hum. Gene Ther. (1995) 6:1531–1541.
   PubMed Web of Science ®Google Scholar
• CHAMBERLAIN RS, CARROLL MW, BRONTE V et aL:
   Google Scholar
• •Costimulation enhances the active immunotherapy ef-fect of recombinant anticancer vaccines. Cancer Res. (1996) 56:2832-2836. This paper demonstrates the therapeutic effects of recombinant vaccinia viruses expressing B7-1 or B7–2.
   Google Scholar
• GREENFIELD EA, HOWARD E, PARADIS T et al.: B7.2 expressed by T-cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: impli-cation for induction of antitumor immunity to T-cell tumors. J. Immunol. (1997) 158:2025-2034. This paper describes that B7-2+ EL4 cells are different from B7-1+ ones in their binding to CD28 and CTLA-4 and in the induction of an antitumour response.
   Google Scholar
• MUSIANI P, MODESTI A, GIOVARELLI M et al: Cytokines, tumor-cell death and immunogenicity: a question of choice. Immunol. Today (1997) 18:32–36.
   PubMedGoogle Scholar
• BISCHOFF JR, KIRN DH, WILLIAMS A et aL: An adenovirus mutant that replicates selectively in p53-deficient hu-man tumor cells. Science (1996) 274:373–376.
   PubMed Web of Science ®Google Scholar
• RHODES J, CHEN H, HALL SR et aL: Therapeutic potentia -tion of the immune system by cotimulatory Schiff-base-forming drugs. Nature (1995) 377:71-75. This paper demonstrates co-stimulatory mimicking drugs.
   Google Scholar